Desogestrel Ethinylestradiol-DWRN desogestrel 150 microgram and ethinylestradiol 30 microgram tablet blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

desogestrel ethinylestradiol-dwrn desogestrel 150 microgram and ethinylestradiol 30 microgram tablet blister pack

arrotex pharmaceuticals pty ltd - desogestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: povidone; titanium dioxide; magnesium stearate; maize starch; hypromellose; polysorbate 80; triacetin; indigo carmine aluminium lake; colloidal anhydrous silica; iron oxide yellow; lactose monohydrate - oral contraception

Desogestrel Ethinylestradiol-RJIC desogestrel 150 microgram and ethinylestradiol 30 microgram tablet blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

desogestrel ethinylestradiol-rjic desogestrel 150 microgram and ethinylestradiol 30 microgram tablet blister pack

arrotex pharmaceuticals pty ltd - desogestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: povidone; titanium dioxide; magnesium stearate; maize starch; hypromellose; polysorbate 80; triacetin; indigo carmine aluminium lake; colloidal anhydrous silica; iron oxide yellow; lactose monohydrate - oral contraception

Alenini 150microgram/20microgram tablets Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

alenini 150microgram/20microgram tablets

actavis uk ltd - desogestrel; ethinylestradiol - oral tablet - 150microgram ; 20microgram

CYRED EQ- desogestrel and ethinyl estradiol kit Spojené státy - angličtina - NLM (National Library of Medicine)

cyred eq- desogestrel and ethinyl estradiol kit

afaxys pharma, llc - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - cyred eq® tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with cyred eq® , 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. emergency contraceptive pills: treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.§ lactation amenorrhea method: lam is

CYRED EQ- desogestrel and ethinyl estradiol kit Spojené státy - angličtina - NLM (National Library of Medicine)

cyred eq- desogestrel and ethinyl estradiol kit

rpk pharmaceuticals, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - cyred eq® tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with cyred eq® , 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. emergency contraceptive pills: treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.§ lactation amenorrhea method: lam is

BEKYREE- desogestrel and ethinyl estradiol and ethinyl estradiol kit Spojené státy - angličtina - NLM (National Library of Medicine)

bekyree- desogestrel and ethinyl estradiol and ethinyl estradiol kit

lupin pharmaceuticals, inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - bekyree (desogestrel and ethinyl estradiol tablets usp and ethinyl estradiol tablets usp) are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. table ii: percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year, united states. among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. b    among typical couples who initiate use of a method (not necessarily for the first time), the per

BEKYREE- desogestrel and ethinyl estradiol and ethinyl estradiol kit Spojené státy - angličtina - NLM (National Library of Medicine)

bekyree- desogestrel and ethinyl estradiol and ethinyl estradiol kit

lupin limited - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - ethinyl estradiol 0.02 mg - bekyree (desogestrel and ethinyl estradiol tablets usp and ethinyl estradiol tablets usp) are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. adapted from hatcher et al., 1998, ref#1. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - known or suspected carcinoma of the breast - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - un

BEKYREE- desogestrel and ethinyl estradiol and ethinyl estradiol kit Spojené státy - angličtina - NLM (National Library of Medicine)

bekyree- desogestrel and ethinyl estradiol and ethinyl estradiol kit

lupin pharmaceuticals, inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - ethinyl estradiol 0.02 mg - bekyree (desogestrel and ethinyl estradiol tablets usp and ethinyl estradiol tablets usp) are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. adapted from hatcher et al., 1998, ref#1. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - known or suspected carcinoma of the breast - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - un